Breaking News, Collaborations & Alliances

Presidio, Boehringer in HCV Pact

Will study respective therapies in Phase II trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Presidio Pharmaceuticals has entered a non-exclusive collaboration with Boehringer Ingelheim for a Phase IIa trial of an interferon-free, oral, direct-acting antiviral (DAA) combination treatment for patients with chronic hepatitis C virus (HCV) infection. The trial will evaluate Presidio’s pan-genotypic HCV NS5A inhibitor (PPI-668) in combination with Boehringer’s HCV protease inhibitor faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor (BI207127), with or without ribavirin....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters